Immunotherapy for non-small cell lung cancer (NSCLC) is incorporated increasingly in first
line treatments protocols. Multiple phase 3 studies have tested different medications …

In recent years, the evolution of treatments has made it possible to significantly improve the
outcomes of patients with non-small cell lung cancer (NSCLC). In particular, while molecular …

Opinion statement Lung cancer is the leading cause of cancer-related mortality worldwide.
Cytotoxic chemotherapy and tyrosine kinase inhibitors provide palliation and prolong …

Immuno-oncology has revolutionized the treatment of metastatic non-small cell lung cancer
(mNSCLC) since the approval of immunotherapy by the US FDA in 2015. Despite the …

Purpose: New therapies are needed to treat immune checkpoint inhibitor–resistant non–
small cell lung cancer (NSCLC) and identify biomarkers to personalize treatment. Epigenetic …

The era of personalized medicine for advanced-stage non-small-cell lung cancer (NSCLC)
began when biomarker-based evidence of molecular pathway and/or oncogene addiction of …

Introduction A series of randomized controlled trials have investigated different first-line
immunotherapy combinations, but the optimal combination strategy is yet to be established …

Introduction Although programmed cell death protein 1 and programmed death-ligand 1 (PD-
L1) blockade in combination with platinum-doublet chemotherapy has become a mainstay of …

Considering retreatment following recovery from an immune-related adverse event (irAE) is
a common clinical scenario, but the safety and benefit of retreatment is unknown. We …

Lung cancer causes significant morbidity and mortality in China and worldwide. In China,
lung cancer accounts for nearly one-fourth of all cancer deaths. Non-small cell lung cancer …